BiotechTube

4 mg CLS-TA + Sham + IVT aflibercept

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Macular Edema

Conditions

Macular Edema, Retinal Vein Occlusion

Trial Timeline

Jan 1, 2015 → Mar 1, 2016

NCT ID
NCT02303184

About 4 mg CLS-TA + Sham + IVT aflibercept

4 mg CLS-TA + Sham + IVT aflibercept is a phase 2 stage product being developed by Clearside Biomedical for Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT02303184. Target conditions include Macular Edema, Retinal Vein Occlusion.

What happened to similar drugs?

20 of 20 similar drugs in Macular Edema were approved

Approved (20) Terminated (3) Active (0)
✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved
✅Ozurdex + AfliberceptAbbVieApproved
✅RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02303184Phase 2Completed

Competing Products

20 competing products in Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or AvastinClearside BiomedicalPhase 3
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved
33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved
33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
Faricimab + AfliberceptChugai PharmaceuticalPhase 3
40
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Fovista® + bevacizumab + ranibizumab + afliberceptAstellas PharmaPhase 2
27
MA09-hRPEAstellas PharmaPre-clinical
26
volociximabAstellas PharmaPhase 1
29